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Introduction
Polymorphism in genes that encode antigen-presenting molecules are crucial determinants of the risk of immunological reactions associated with both allogeneic hematopoietic stem cell transplantation and most solid organ transplantations. Distinct peptide motifs and peptide-binding features have been described for a variety of alleles across major allotypic groups which differ by [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] amino acids in the region of their antigen-binding cleft. 1 Hence differences in peptide selection can be reconciled with the nature of the individual human leukocyte antigen (HLA) allotypic polymorphism. However, only a few studies have addressed the extent to which variants of the same allelic group differ in their peptide motifs and are truly functionally distinct. Understanding the factors that make some mismatches more important than others, and appreciating the optimal match for a transplant candidate, requires a deeper knowledge of how HLA polymorphism affect peptide selection and T-cell responsiveness.
Mismatches within the HLA heavy chain which are predicted to contact a bound peptide appear to be more important in dictating cellular responses than those that are positioned outside of the peptide-binding region because they can affect the peptide binding motif. 2, 3 However, the magnitude of a given polymorphism is not dependent only on its position but also on the nature of the exchanged amino acids, as well as their neighboring amino acids. Even small differences between HLA allotypes can have dramatic effects on their function and the selection criteria for identifying acceptable mismatches when no matched donor is available still remain poorly defined.
Scoring matrices, hidden Markov models, and artificial neural networks are examples of algorithms that have been successful in predicting major histocompatibility complex (MHC) peptide-binding. [3] [4] [5] [6] [7] However, because these algorithms are based on a limited amount of experimental peptide-binding data, prediction is only possible for a small fraction of known MHC proteins. Many groups have conducted sequencing analyses of naturally presented MHC peptides from both native membrane-bound molecules 8 and recombinant membrane-bound or secreted molecules. 9 These binding data are needed in order to identify the specific binding motifs and preferred peptide anchor residues for given alleles. They allow potential binding peptide sequences to be predicted by T-cell epitope prediction algorithms such as SYFPETHI, 10 NetMHC, 11 RANKPEP, 12 PeptideCheck 13 and BIMAS. 14 One failing of these programs is that they cannot address the presentation of peptides longer than the normal 8 to 10 mers. 15 Unusually long peptides with 12 or more residues which are naturally processed by the cellular machinery reportedly have quite high binding affinities (BadeDoeding et al., 2010, unpublished data) 16 and thus elicit strong T-cell responses, 17 making them clinically important in both transplantation and adoptive T-cell therapies.
The aim of the present study was to understand the structural and functional factors underpinning differences in ligand selection within a selected group of HLA-B allotypes. Peptide-binding motifs and peptide features of HLA-B*41:01, *41:02, *41:03, *41:04, *41:05 and *41:06 were investigated because all but two of their polymorphic differences are located within the peptide-binding region and were, therefore, predicted to influence the sequence and conformation of the presented peptides.
Design and Methods

Production of eukaryotic soluble recombinant HLA-B*41 molecules
mRNA of HLA-B*41:01 (exon 1 through exon 4, encoding the signal peptide and the α1-α3 domains) was amplified by reverse transcriptase polymerase chain reaction using the primers HLA-B3-TAS (5'GAGATGCGGGTCACGGCAC-3') and HLA-E4-WAS (5'CCATCTCAGGGTGAGGGGCT-3'). The polymerase chain reaction product was cloned in the eukaryotic expression vector pcDNA3.1V5/His (Invitrogen, Karlsruhe, Germany) as previously described. 18 Further HLA-B*41 expression constructs were produced by site-direct mutagenesis using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene, Amsterdam, The Netherlands).
Transfection of expression constructs (pcDNA-B4101, pcDNA-B4102, pcDNA-B4103, pcDNA-B4104, pcDNA-B4105 and pcDNA-B4106) in the human embryonic kidney cell line HEK293 was performed by lipofection (Lipofectamine, Invitrogen).
Expression and purification of soluble human leukocyte antigens
High-expressing G418-resistant clones were individually selected 10 to 16 days after the addition of selection medium to obtain stable cell lines. Quantification of soluble HLA-B41 proteins was performed using a sandwich enzyme-linked immunosorbent assay (ELISA) in which the monoclonal antibodies anti-HLA-A-B-C W6/32 (Serotec, Düsseldorf, Germany) 19, 20 or anti-V5 (Invitrogen), respectively, were employed as capture antibodies. Horseradish peroxidase-conjugated anti-β2 microglobulin monoclonal antibody (DAKO, Hamburg, Germany) served as the detection antibody. HEK293 clones with the highest expression levels were used for largescale production in roller bottles. Soluble HLA molecules were purified from the supernatants using N-hydroxysuccimideactivated HiTrap columns (GE Healthcare, Munich, Germany) coupled with monoclonal antibody W6/32. Affinity chromatography was performed using the Äctaprime system (Amersham Pharmacia Biosciences).
Isolation and characterization of self-peptides
Peptides were eluted from soluble HLA molecules by acidic treatment and separated from the heavy chain and β2 microglobulin molecules by size exclusion. For desalting and purification, reverse-phase high performance liquid chromatography was performed using the HP 1100 (Agilent Technologies, Böblingen, Germany). Subsequently, peptides were sequenced using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF, MALDI MS/MS) (Proteomic Analyzer 4700, Applied Biosystems, Foster City, CA, USA). A database search using MASCOT 21 and BLAST 22 was performed to determine peptide sources.
HEEAVSVDRVL crystals were grown at 21 ºC using protein concentrations of 4.1 mg/mL and 1.1 mg/mL, respectively; the crystals were obtained by seeding from HLA-B*35:08/FPT (sharing greater than 93% sequence identity in the alpha chain) 24 in 0.1 M citrate buffer pH 5.6, PEG 4000 (14-20%), and 0.2M NH4OAc. The crystals were cryoprotected by equilibration against mother liquor containing 30% PEG 4000 and flash-frozen in liquid nitrogen. Data sets were collected at 100 K at the Stanford Synchrotron Radiation Lightsource (SSRL) and processed with XDS and XSCALE. 25 The crystal structures were solved by molecular replacement in PHASER 26 against a HLA-B*4405 complex (sharing 94% identity in the alpha chain) (PDB entry 1SYV 27 ). The resultant models were subjected to iterative cycles of refinement in REFMAC5 28 and then PHENIX, 29 followed by model building/correction in O 30 and COOT. 31 The solvent structures were built using ARP/wARP 32 and COOT. The high resolution of the B*4103/16-mer structure permitted the refinement of anisotropic displacement parameters during the final rounds of refinement in PHENIX, resulting in a distribution of anisotropy with a mean of 0.46 and standard deviation of 0.14, as determined using the PARVATI server. 33 Structure/model validation was carried out using COOT, MOLPROBITY and the CCP4i implementation of SFCHECK. 34 The data processing and refinement statistics for the two structures are summarized in Table 1 .
Computational analysis
The disordered central region of the 16-mer peptide in the B*41:03 structure (residues -G5-SVTEHP-S12-) was modeled using COOT and the 'model_anneal' protocol in CNSsolve. 35, 36 Briefly, the disordered residues were built into the model and their stereochemistry regularized using COOT, resulting in two Ramachandran outliers as determined by the MOLPROBITY server. 37 The model was then subjected to torsion angle dynamics combined with simulated annealing from 5000 K, in which all residues were fixed except for Y4-S14. Of five trials carried out at different initial velocities, one model was obtained in which the Ramachandran outliers were reduced to one (His10).
Protonation equilibrium (pK) constants were calculated using the H++ server (http://biophysics.cs.vt.edu/H++). 38 The input models were derived by removing solvent molecules and alternative conformers from the coordinates of the B*41:03/16mer and B*41:04/11mer structures. Separate runs were carried out in the presence and absence of the peptide coordinates. In the case of B*41:03, the modeled coordinates for the full length peptide were used (see above). The following physical conditions εsolute = 10, εsolvent = 80, salt = 0.15 M, and the Poison-Boltzmann method were used. An intermediate value for the internal dielectric was chosen based on the calculated desolvation penalties for the residues of interest, which generally had an absolute value of 1-3pK units.
Results
Subtle differences in peptide-binding motifs for HLA-B*41 subtypes
Individual peptide sequences derived from the six B*41 allotypes (B*41:01 to B*41:06) determined by mass spectrometry are shown in Online Supplementary Table S1. Sixteen ligands were eluted from B*41:01, the majority of which were nonameric peptides ( Table 2 ). Peptide anchors were determined to be Glu at position p2 and Val/Pro at position pΩ based on the frequency of residues in this position (Table 3) . Twenty-one ligands of B*41:02 were isolated, among which octa-, nona-and decameric peptides were frequent ( Table 2 ). Among the B*41:02-derived peptides, Glu was found to be the p2 anchor while Leu was the pΩ anchor motif ( Table 3 ). The same anchor motifs were identified from the 85 eluted B*41:03-bound ligands ( Table 3 ). The majority of these peptides were nonamers and decamers (Table 2) . Interestingly, B*41:03 yielded no octamers and had the longest peptide eluted from any of these related allotypes (a 16-mer). In addition, 52 ligands were identified from B*41:04, about half of which were 11 to 15 amino acids in length ( Table 2) . Their anchor motifs were the same as for B*41:02 and B*41:03 (Table 3) ; an auxiliary anchor (Glu) was detected at position p3 of the B*41:04-derived peptides (Table 3 ). In the case of B*41:05, we detected 41 ligands, which were anchored predominantly by Glu at p2 and by Leu, Val and Pro at pΩ (Table 3) . Eighteen of these ligands (nearly 44%) were non-canonical in length (11 to 13 amino acids) ( Table  2 ). The tendency of B*41:05 to tolerate more promiscuous peptide anchoring at pΩ compared with B*41:01 appears to be associated with polymorphic position 80. Modeling studies previously suggested that Lys80 (unique in B*41:05) has the effect of relaxing the binding properties of pocket F, by extending the cavity that accommodates the C-terminus of the peptide. 39 The 22 were up to 14 amino acids in length, although more than 40% were octamers (Table 2) . Their anchor motifs were Glu at p2 and Val and Pro at pΩ (Table 3) .
Shared peptide specificities within the B*41 allotypic family
Peptide sequencing showed that the six B*41 subtypes investigated in this study bind overlapping sets of peptides (Online Supplementary Table S2 ). As the B*41 alleles were all expressed in the same cell type (HEK293 cells), their source of potential ligands was identical and the subtypes acquired a shared set of intracellularly available peptides. Peptides detected in more than one B*41 subtype are listed in Online Supplementary Table S2 . For example, the nonamer KEGKPPISV (unnamed protein product, human) and the decamer YEEGPGKNLP (cytochrome C oxidase VIIc) were eluted from both B*41:01 and B*41:02, while the decamer IEVDGKQVEL (Rho-related GTP-binding protein) was found in three B*41 variants (B*41:02, 41:03 and 41:04).
Notably, the shared peptides do not conform rigorously to the general anchor motifs of the B*41 specificities.
Differential selection of peptides
Some of the B*41-derived ligands were derived from the same protein and had overlapping sequences (Online Supplementary Table S3 ). These peptides differed both in their length (8 to 14 amino acids) and in their primary anchor residues. The shorter peptide versions were Nand/or C-terminally truncated, and related peptides were detected in distinct B*41 alleles.
A nonameric peptide derived from protein C20orf24, group, with a single heterodimer in the asymmetric unit. The N-and C-terminal residues of the 16-mer were located within the antigen-binding cleft, while the central region of the peptide was found to be disordered (Online Supplementary Figure S1A) . Although the structural database (PDB) 40 includes several entries of peptides as long as 14 residues in complex with MHC class I molecules (PDB entry 1XH3), these structures are characterized in some cases by significant disorder [(1XH3, 41 2FYY, 42 2NW3 43 ] in the central bulged region of the peptide, consistent with a high degree of mobility. This was true of the B*41:03-AEMYGSVTEHPSPSPL complex where eight residues of the peptide, namely pAla1-pMet3 and pSer14-pLeu16 appear well ordered, while pTyr4 -pPro13 are partially, or completely, disordered. In their observed conformations, the side chains of pAla1, pTyr4, pPro13 and pPro15 point out of the antigen-binding cleft, whereas those of pGlu2 and pLeu16 are buried deep within the cleft, and pMet3 and pSer14 are oriented towards the α2 helix ( Figure 1A) . pAla1, pGlu2, pMet3 and pLeu16 form the majority of direct contacts with the HLA heavy chain (Online Supplementary  Table S4 ). More specifically, p1 of the peptide forms hydrogen bond interactions with the HLA Tyr7, Tyr159 and Tyr171 (Figure 2A ). Position p2 of the peptide forms a hydrogen bond with Arg62 and Glu63 via its main chain and with Tyr99 via its side chain ( Figure 2C ). The residue also forms potential ionic interactions with His9 and Lys45 and significant van der Waals (VDW) contacts with Tyr7. p3 forms a hydrogen bond with Tyr99 via its main chain and with Asp156 via its side chain while also sharing an extensive VDW surface with Tyr159 ( Figure 2E ). The side chain of p3 is observed in two distinct conformations in the structure and in one of these, the residue also forms a watermediated hydrogen bond with Arg97. p15 is in contact with Thr73, Glu76, and Ser77 via VDW interactions and forms a hydrogen bond with Trp147 ( Figure 2G ). The main chain of p16 forms hydrogen bond interactions with Ser77, Asn80, Tyr84 and Thr143 as well a salt bridge with Lys146. In addition, its side chain is buried within a hydrophobic pocket, where it makes VDW contacts with a number of residues, including Leu95, Tyr116 and Trp147 ( Figure 2I ).
Crystal structure of HLA-B*41:04/HEEAVSVDRVL
The structure of the B*41:04/HEEAVSVDRVL (11-mer) complex was solved to a resolution of 1.9 Å in the P212121 space group, with a single heterodimer in the asymmetric unit. The 11-mer peptide was clearly bound in the antigen-binding cleft of the HLA heavy chain in a partially extended conformation (Online Supplementary Figure 1B) , and a nearly 310-helical turn formed between positions Val7 and Arg9 (DSSP assignment 44 ). All residues of the peptide appear structurally ordered and conformationally unambiguous. Briefly, the side chains of pHis1, pAla4, pSer6-pAsp8 and pVal10 point out of the antigen-binding cleft. pGlu2, pVal5 and pLeu11 point down towards the floor of the cleft, while the side chains of pGlu3 and pArg9 are oriented towards the heavy chain's α2 helix ( Figure 1B) . Furthermore, positions pHis1-pGlu3 and pArg9-pLeu11 interact predominantly with the HLA heavy chain, while pAla4 and pSer6-pAsp8 are prominently surface exposed and expected to be important in T-cell receptor recognition.
Online Supplementary Table S4 contains an extensive list of contacts for each peptide position. The most important peptide-HLA interactions are described below. p1 forms hydrogen bond interactions with Tyr7, Tyr159 and Tyr171 via its main chain, while its side chain shares a significant VDW surface with Trp167 ( Figure 2B ). p2 forms hydrogen bond interactions via its backbone and side chain with Glu63 and Tyr99, respectively, while also forming potential ionic interactions with His9 and Lys45, and VDW contacts with Tyr7 ( Figure 2D ). The main chain of p3 forms a hydrogen bond with Tyr99 and interacts with Asp156 via its side chain. P3 also shares an extensive VDW surface with Tyr159 ( Figure 2F ). The side chain of p8 is involved in a hydrogen bond with Gln155, while the side chain of p9 interacts with two additional residues, Asp114 and Asp156. p10 forms a hydrogen bond with Trp147 via its main chain and VDW contacts with Glu76 and Ser77 via its side chain ( Figure 2H) . Finally, the backbone of p11 forms hydrogen bond interactions with Ser77, Asn80, Tyr84 and Thr143 as well as a salt bridge with Lys146 ( Figure 2J ). The side chain of p11 is buried within a hydrophobic pocket and forms VDW contacts with a number of residues, including Leu95, Tyr116,
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haematologica | 2011; 96(1) In each case the MHC is presented in cartoon format (B*41:03, green; B*41:04, blue) and the α-2 helix of the heavy chain has been removed for clarity. The peptide residues are drawn as sticks (16mer, light red; 11mer dark red), as are selected side chains of the MHC. Peptide residues are labeled in italics. The polymorphic residues distinguishing the two alleles are also shown, highlighting the size/charge differences associated with the R97S/N114D substitutions. In the case of the B*41:03/16mer complex (A, C), the central disordered region of the peptide was modeled and is presented here in ribbon format. The superposition (C) demonstrates that the N-and C-terminal regions of the two peptides adopt equivalent conformations, while the central region of the 16mer is expected to diverge significantly in conformation with respect to the 11mer. Moreover, the superposition also helps to highlight the significant difference in surface area that each peptide might present to T-cell receptor. Based on the modeled central region, the 16mer peptide is expected to have an exposed surface that is 650 Å2 greater than that of the 11mer when bound to one of the B*41 alleles (determined using the CCP4i implementation of AREAIMOL.
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Tyr123 and Trp147. In addition to these interactions, the B*41:04/HEEAVSV-DRVL (11-mer) complex is characterized by a large number of contacts between residues of the peptide, which constrain its conformation within the antigen-binding cleft (type III constraints 45 ). The side chain of p1 forms a hydrogen bond with the main chain carbonyl of p2; in addition, the side chain of p5 shares an extensive VDW surface with p3 and p9. Moreover, positions p6 to p10 display a characteristic 310-helix main chain hydrogen-bonding pattern (i→i-3), while additional hydrogen bonds and VDW contacts are observed between the main chain and side chain groups of p6-p8. Of particular interest, however, are p3 and p9, the side chains of which form a network of contacts with each other and with the side chains of Asp114 and Asp156. More specifically, the carboxylate of Asp156 is within interacting distance of the equivalent groups on Asp114 and pGlu3, and Asp156 together with pGlu3 are in a position to form a salt bridge with the guanidinium group of pArg9. The latter is, therefore, particularly important in stabilizing this network and thus the pHLA complex by providing a countercharge to the two pairs of proximal acidic residues. Figure S2 ). Therefore, while B*41:04 displays an overall negative charge within the central region of the cleft, that of B*41:03 is clearly more electropositive in character. The 11-mer and 16-mer peptides display significant differences in mobility of their crystal structures, indicating that the central regions of these two peptides interact very differently with their respective HLA. By contrast, their Nand C-terminal regions adopt equivalent conformations and interact with similar sets of heavy chain residues (Figures 1 and 2; Online Supplementary Table S4 ). This is particularly evident at the primary anchor positions (p2 and pΩ), which are conserved in the two peptides ( Figure  2C, D, I , J). The only difference at either of these positions relates to Arg62, which is unable to interact with the main chain of p2 in the B*41:04/11-mer complex due to the presence of the histidine side chain at p1 of the peptide. Instead, the side chain of Arg62 appears partially disordered in this structure. The two structures also display striking similarities at positions p1, p3 and pΩ-1 of the peptides (Figure 2A , B, E, F, G, H), and although not conserved, these residues occupy equivalent positions and interact in a similar manner with the heavy chain.
Impact of human leukocyte antigen polymorphism on
Of particular interest is a network of interactions involving position p3 of the peptides and the two polymorphic heavy chain positions (97 and 114), as it appears that B*41:03 and B*41:04 compensate for their polymorphic differences in order to maintain this network. Thus, as part of this network, the side chain of Asp156 maintains an interaction with that of residue 114 in both structures, despite the unfavorable substitution of an asparagine for an aspartate at position 114 in B*41:04 (Figure 3) .
Conversely, the side chain of residue 97 does not participate in the network of interactions in B*41:04, but is incorporated into this network in B*41:03, in which allele it is substituted from a serine to an arginine, thereby providing a positive charge within pocket D to balance the negative charge of Asp156.
Surprisingly, B*41:04 does not possess a countercharge for the aspartic acids at 114 and 156 within pocket D (corresponds with p3 of a given peptide). In the case of the B*41:04/11-mer complex it appears that this charge imbalance is compensated for by the peptide, in the form of pArg9. Therefore, in addition to stabilizing the peptide conformation through intra-peptide contacts with pGlu3 and pVal5, pArg9 may also contribute to the greater stability of the 11-mer complex by participating in the network of interactions between Asp156, Asp114 and the peptide's auxiliary anchor (pGlu3). However, based on the peptide elution data (Online Supplementary Table S1 ) there is no evidence to suggest that such peptide contributions constitute a requirement for binding to B*41:04.
The protonation equilibrium (pK) constants of titratable residues were calculated computationally using the atomic coordinates of the two B*41 high resolution structures. The results demonstrate that Arg97 in B*41:03 not only provides a countercharge to the acidic Asp156, but actively promotes its negatively charged state (Online Supplementary  Table S5 ). By contrast, the R97S/N114D double substitution in B*41:04 creates a local environment for Asp156 which strongly favors the protonated state at physiological pH. Given the close proximity between the carboxylate groups of Asp156 and pGlu3 observed in the B*41:04/11mer complex, the absence of a negative charge on Asp156 is expected to significantly reduce the repulsive forces between the two groups.
Binding of pGlu3 in a similar manner to B*41:03, on the other hand, is expected to be less favorable, particularly given that the crystal structure suggests only a weak interaction between Asp156 and Arg97. 47 Furthermore, the N114D substitution (a feature unique to the B*41:04 allele) was found to be essential to the observed perturbation in the protonation equilibrium constant of Asp156. Thus, by using the high resolution crystallographic data in conjunction with powerful pK calculation algorithms we were able to obtain compelling evidence that explains how the polymorphism in B*41 gives rise to an environment within the antigen-binding cleft of the B*41:04 allele which uniquely favors the pGlu3 auxiliary anchor.
Interestingly, the pK predictions also suggest an effect of polymorphism on the nature of the interactions involving the pGlu2 primary anchor. While in B*41:03 the local environment of His9 strongly favors the deprotonated state, the R97S substitution in B*41:04 gives rise to a pK consistent with His9 being more positively charged at physiological pH. Consequently, in B*41:04 the pGlu2-His9 interaction is likely to be more ionic in character. Given that Lys45 (the only other residue able to form a salt bridge with pGlu2) is expected to form an ion pair with Glu63, the potential for pGlu2 to ion pair with pHis9 may have a significant effect on the nature of the peptide anchoring. Table 3) .
Discussion
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are 80, 95, 97, 103, 114 and 180 (Table 3) . Amino acid residues 103 and 180 are located in outer loop positions, and are not, therefore, directly involved in peptide binding. By definition, residues 80 and 95 are part of the F pocket and thus critical for binding at the pΩ position of the peptide. According to the pocket definition of Chelvanayagam, 1 residues 97 and 114 within the center of the peptide-binding region are designated as part of four pockets (C, D, E and F) and are thus predicted to contact bound peptides at positions 3, 6, 7 and pΩ when considering canonical peptides 8 to 10 amino acids in length.
Based on the peptide-binding analysis, we were able to divide the B*41 molecules into two specificity subsets, B*41:01/B*41:05-06 (Trp95) and B*41:02-04 (Leu95), in terms of pΩ specificity. The presence of Leu95 in the peptide-binding region was associated with Leu at position pΩ of bound peptides, whereas Trp95 was associated with Val/Pro in the pΩ motifs. 39 While position 97 is presumed to also affect pΩ preference, our peptide binding analysis did not identify a link between pΩ specificity and mismatches at amino acid 97 in the six B*41 variants. This is highlighted by B*41:02 and B*41:03, which differ by a single amino acid residue, Ser97Arg, yet share the same peptide-binding anchor motif at pΩ.
Our peptide elution data derived from B*41:04 also highlighted a unique preference for a Glu auxiliary anchor at peptide position p3, which correlates with the presence of an Asp at position 114 within the peptide-binding region of B ). An effect of amino acid position 114 on pocket D (which corresponds with position 3 of a given peptide) was predicted and has also been observed for the B7 group. 48 While a total of 237 peptides, varying in length between 8 and 16 amino acids, were eluted from the B*41 group, their distribution varies significantly between the six alleles. Predominantly peptides of canonical length (8-10 amino acids) were eluted from B*41:01 and 02, while no octamers were eluted from B*41:03. Also, although multiple peptides of non-canonical length (≥11 amino acids) were eluted from B*41:03-06, B*41:04 exhibited a statistically significant preference for ligands of non-canonical length over the other alleles ( Table 2 ). The B*41:04-derived ligands also showed more divergent peptide-binding characteristics, namely, an average peptide length of 10.5 amino acids. B*41:03 yielded the only 16-mer self-peptide.
Several long T-cell epitopes for HLA class I molecules have been predicted by extending known shorter epitopes or by screening peptide libraries, including an overlapping 16-mer, 49, 50 and several 15-mer peptides. 51, 52 MHC class I molecules bind peptides with a length of up to 25 amino acids. 53 B*41:03 yielded 85 ligands. To explain these findings, we solved the X-ray crystal structures of the B*4103/AEMYGSVTEHPSPSPL (16-mer self-peptide) and B*4104/HEEAVSVDRVL (11-mer self-peptide) complexes. These structures show that B*41:03 and B*41:04, which share conserved primary anchor motifs, interact in a highly conserved manner with the terminal regions of two distinct peptides. However, the two structures also reveal certain roles in peptide binding for the polymorphic residues 97 and 114 that could not be predicted based on the knowledge of peptide feature information alone.
Contrary to previous pocket definitions, 1, 54 the side chain of Arg97 extends out of the floor of the antigen-binding cleft of B*41:03 and contacts the p3 residue of the peptide, thereby forming part of pocket D. Moreover, residue 114 in the B*41:04/11-mer structure contacts the p9 residue of the peptide directly, while only interacting with the p3 residue indirectly via p9 and Asp156.
Micropolymorphism at positions 97 and 114 affects not only the size of the antigen-binding cleft in the region of pocket D, but also the pocket's electrostatic properties. Furthermore, combined with computational analysis the structural data provide compelling evidence that the auxiliary anchor motif at p3, unique to B*41:04, is brought about by the modulation of the neighboring Asp156's protonation state by the polymorphic positions 97 and 114. This auxiliary anchor is anticipated to confer greater stability to peptide complexes formed with B*41:04, while also permitting more diverse binding modes. We are thus able to correlate micropolymorphism with the significant differences in peptide repertoire observed between B*41:03 and B*41:04, as well as the apparent ability of B*41:04 to accommodate a broader range of peptide lengths compared to the other B*41 alleles.
Overall, our analysis has resulted in a detailed characterization of the binding characteristics of the B*41 variants. 
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